Experts Anticipate a Growing Menu of Frontline Options in Liver Cancer

Christin Melton, ELS
Published: Wednesday, Jul 04, 2018
Aiwu Ruth He, MD, PhD

Aiwu Ruth He, MD, PhD

The recent introduction of novel therapies for patients with hepatocellular carcinoma (HCC) ended a 10-year drought in new drugs for the tumor type and may represent the leading edge of a wave of change in how the malignancy is managed, according to experts who participated in an OncLive Peer Exchange® program.

The panelists reviewed data for lenvatinib (Lenvima), which is under priority review by the FDA as a firstline treatment for HCC, and for novel drugs under investigation in the second line, such as cabozantinib (Cabometyx/Cometriq) and pembrolizumab (Keytruda). The panelists agreed that although novel treatments offer benefits, they introduce new challenges for clinicians, including sequencing and management of adverse events (AEs), especially for patients with comorbid liver diseases.

Emerging First-Line Approaches

Lenvatinib
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x